Science Corporation Raises $400 Million to Scale PRIMA Vision System
PRIMA is approved in Europe, and Science is pursuing U.S. approval through the Humanitarian Device Exemption pathway.

Science Corporation raised $400 million in a Series D round to scale its vision-restoration business.
Investors in the round included Khosla Ventures, the Ackman Oxman Institute, Tenet Healthcare, 885 Capital, Y Combinator and PLC Neurotech.
PRIMA combines wearable and implantable components. PRIMA is approved in Europe and available in Germany. It can help people with age-related macular degeneration recover some vision. Science launched PRIMA commercially in Europe in July.
The Food and Drug Administration (FDA) has granted PRIMA Humanitarian Use Device designations for certain patients with advanced macular degeneration and for people who have lost vision from Stargardt disease. Those designations are distinct from approval to market the system in the United States. Science is pursuing FDA approval through the Humanitarian Device Exemption pathway.
The company also plans to invest part of the new funding in a separate neural interface program that uses engineered neurons.